Dr Trudy Sullivan
Dr Trudy Sullivan is a health economist consultant at the Dunedin School of Medicine, and a lecturer in the Department of Preventive and Social Medicine, University of Otago. Trudy's main research interests lie in the areas of health economics and programme evaluation, public health and wellbeing, and the use of multi-criteria decision analysis (MCDA) in priority-setting.
Anita Fitzgerald is a Scientific Research Consultant for the Northern Region Clinical Practice Committee (NZ) and York Health Economics Consortium (UK). In NZ, she conducts hospital-based health technology assessments to inform investment and disinvestment decisions for the four northern DHBs. In the UK Anita conducts systematic reviews for York Health Economics Consortium to inform economic models for the NHS, NICE, pharmaceutical and other healthcare companies.
Susan originally trained as a nurse and has worked in the pharmaceutical industry. She has also gained post graduate qualifications in both Health Management and Public Health, from Auckland University.
Her interests in healthcare centre round evidence based medicine, health outcomes, economics and policy. She has completed research into New Zealand’s Medicines Policy and medicines access, with a focus on ethnic inequities, PHARMAC and High Cost Medicines.
Professor Carlo Marra [BSc (Pharm),PharmD, PhD] is Dean of the School of Pharmacy at the University of Otago. Professor Marra completed a PhD in health economics/health outcomes research at the University of British Columbia in 2004 but has been active in health economics research since 1995 as a research pharmacist at Vancouver General Hospital in Canada. Professor Marra has published more than 250 peer-reviewed manuscripts and has presented at more than 150 international conferences. Professor Marra’s research interests are economic evaluation of health care programmes and strategies, patient preferences, and choice experiments. Professor Marra is an Associate Editor (Health Economics) for the journal Arthritis Care and Research.
James is a health economist in the New Zealand public sector. As Manager Health Economics at PHARMAC, he led the team responsible for New Zealand's economic assessments of new pharmaceuticals, vaccines, and medical devices.
Previously James consulted to the pharmaceutical industry in Australia, and advised New Zealand health funders on technology assessments and future demand for health services.
Richard Milne [BSc (Hons), MSc, PhD] was a founding member of ISPOR. He trained in physics/maths, physiology/ pharmacology, neuroscience and health economics in NZ and the USA. He has been researching the epidemiology and economics of healthcare interventions since 1997. He has published over 50 peer reviewed articles in physics, physiology, pharmacology, medicine and health economics and is an Advisory Board member on the leading peer reviewed Journal PharmacoEconomics. Richard is Honorary Associate Professor at the University of Auckland and Managing Director of Health Outcomes Associates Ltd.
Ross Wilson [BCom(Hons), PhD] is a research fellow at the Centre for Musculoskeletal Outcomes Research, University of Otago. His research interests are in the valuation of health-related quality of life (HRQoL), economic evaluation of healthcare interventions, and simulation modelling of disease epidemiology and treatment to inform health care policy.
William Leung, MSc (Health Econ) MSc (Op Res) MSc (Comp Sci), is a senior lecturer in health economics at the University of Otago, Wellington, and consulting health economist at the Dunedin School of Medicine. Prior to receiving his master’s degree at York, he worked in the UK NHS and other government agencies as an analyst. Recent projects have included an economic evaluation funded by US CDC and an operational research study with MfE.
Carsten is a Senior Health Economist at PHARMAC undertaking economic assessment on new pharmaceuticals, vaccines and medical devices. Carsten previously worked at New Zealand Treasury and Novo Nordisk. Carsten is currently a PhD student at Otago university where he is researching the measurement properties of Health Related Quality of Life instruments.
Chris Carswell practised as a pharmacist for over 10 years before becoming a full-time professional journal and books editor with Adis International in 2001. He is the Editor in Chief of two of the leading international health economics and outcomes research journals: PharmacoEconomics and The Patient:Patient-Centered Outcomes. He also leads a team of six other professional journal editors in the pharmacokinetic and pharmacovigilance fields and is responsible for commissioning health economics and outcomes research books for Adis International. Chris was a lead author on the recently published Consolidated Health Economic Evaluation Reporting Standards Guidelines (CHEERS) and Good Publication Practice for the Pharmaceutical Industry (GPP-3) guidelines.
ISPOR (NZ) is the only scientific organisation in New Zealand that brings together health care scientists, professionals and providers, academics, procurement and budget holders, suppliers, publishers, policy makers and others interested in the economics of healthcare interventions. Our aim is to provide an environment that enables collaborative sharing of knowledge and to act as a resource for those interested in health technology economics and outcomes research.